Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | KDM4B | O94953 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.37 |
| ▸ | TNKS | O95271 | 3/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.36 |
| ▸ | PARP1 | P09874 | 6/20 | 0.36 |
| ▸ | GUSB | P08236 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3040246 | 0.84 | PARP1 (0.43) | KDM4AKDM4BKDM5CKDM5BNPC1 | |
| SCHEMBL3040436 | 0.84 | PARP1 (0.56) | TNKSTNKS2PARP2PARP1 | |
| SCHEMBL3025074 | 0.84 | PARP1 (0.54) | KDM4AKDM4BKDM5CKDM5BNPC1 | |
| SCHEMBL3039605 | 0.81 | EGLN1 (0.43) | KDM4AKDM4BKDM5CKDM5BNPC1 | |
| SCHEMBL3030437 | 0.77 | HTR3A (0.52) | NPC1MAPK1EGLN1TNKSTNKS2 | |
| SCHEMBL3036576 | 0.75 | EGLN1 (0.58) | EGLN1 | |
| SCHEMBL3027794 | 0.75 | TUBB4A (0.48) | KDM4AKDM4BKDM5CKDM5BNPC1 | |
| SCHEMBL3025380 | 0.75 | AURKA (0.38) | KDM4AKDM4BKDM5CKDM5BNPC1 | |
| SCHEMBL16857710 | 0.73 | EGLN1 (0.40) | EGLN1GUSB | |
| SCHEMBL2555865 | 0.73 | ADORA2A (0.49) | KDM4AKDM4BKDM5CKDM5BEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937078-B2 | Quinazolinones as prolyl hydroxylase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-20 | — | — | US | disclosed |
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204226-A1 | QUINAZOLINONES AS PROLYL HYDROXYLASE INHIBITORS | P4HA1, EGLN3, EGLN2 | KDM4A 797/4885KDM4B 1172/4885KDM5C 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.